| Gene Symbol | CEBPA |
|---|---|
| Entrez Gene | 1050 |
| Alt Symbol | C/EBP-alpha, CEBP |
| Species | Human |
| Gene Type | protein-coding |
| Description | CCAAT/enhancer binding protein (C/EBP), alpha |
| Other Description | CCAAT/enhancer-binding protein alpha |
| Swissprots | P78319 P49715 Q05CA4 A7LNP2 |
| Accessions | AAC50235 ABS82765 P49715 BC027902 AAH27902 BC063874 AAH63874 BC160133 AAI60133 X87248 CAA60698 Y11525 CAA72289 NM_001285829 NP_001272758 NM_001287424 NP_001274353 NM_001287435 NP_001274364 NM_004364 NP_004355 |
| Function | Transcription factor that coordinates proliferation arrest and the differentiation of myeloid progenitors, adipocytes, hepatocytes, and cells of the lung and the placenta. Binds directly to the consensus DNA sequence 5'-T[TG]NNGNAA[TG]-3' acting as an activator on distinct target genes (PubMed:11242107). During early embryogenesis, plays essential and redundant functions with CEBPB. Essential for the transition from common myeloid progenitors (CMP) to granulocyte/monocyte progenitors (GMP). Critical for the proper development of the liver and the lung (By similarity). Necessary for terminal adipocyte differentiation, is required for postnatal maintenance of systemic energy homeostasis and lipid storage (By similarity). To regulate these different processes at the proper moment and tissue, interplays with other transcription factors and modulators. Downregulates the expression of genes that maintain cells in an undifferentiated and proliferative state through E2F1 repression, which is c |
| Subcellular Location | Nucleus {ECO:0000269|PubMed:11242107}. |
| Top Pathways | Acute myeloid leukemia, Non-alcoholic fatty liver disease (NAFLD), Transcriptional misregulation in cancer |